MG01-T521 is under clinical development by Inmunotek and currently in Phase III for Allergic Rhinitis. According to GlobalData, Phase III drugs for Allergic Rhinitis have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how MG01-T521’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MG01-T521 is under development for the treatment of allergic rhinitis, allergic rhinoconjunctivitis and allergic asthma due to grass and Cupressaceae pollen. It is administered through subcutaneous route. It comprises of purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and cupresaceae (Juniperus oxycedrus), adsorbed on aluminum hydroxide.
Inmunotek opearates as a pharmaceutical company. It develops, produces and markets products for allergy and other immune-based diseases and manufactures veterinary medicine. It also produces raw materials such as biological products, including fungi, bacteria and mites.
For a complete picture of MG01-T521’s drug-specific PTSR and LoA scores, buy the report here.